Ironwood (IRWD) Q2 EPS Jumps 600%

Ironwood Pharmaceuticals (NASDAQ:IRWD), a specialty pharmaceutical company known for developing therapies for gastrointestinal conditions, delivered financial results on August 7, 2025, for its second quarter. The company beat analyst expectations on both non-GAAP earnings and GAAP revenue. Non-GAAP earnings per share (EPS) came in at $0.14 versus the $0.02 consensus, while reported GAAP revenue of $85.2 million surpassed the $60.8 million projection. Despite this outperformance, the revenue figure (GAAP) was down from the prior year due to non-recurring adjustments in Q2 2024. The quarter showed continued strong prescription growth for its lead product, LINZESS, with total prescription demand increasing 10% year-over-year, and profitability improvements, though underlying revenue recognition volatility and pipeline concentration remain key themes for the period. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Ironwood Pharmaceuticals develops and commercializes treatments for gastrointestinal (GI) diseases. Its most important product, LINZESS (linaclotide), is a prescription capsule aimed at adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company’s business rests on maximizing demand for LINZESS in the United States through collaboration with AbbVie, and expanding sales in international markets through partnerships.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool